Analysts have clear opinions on RCKT.

There are 5 analysts on the Wall offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $38.67 with a high forecast of $42.00 and a low forecast of $33.00. The average price target represents a 62.68% increase from the last price of $23.77.
Rocket Pharmaceuticals, Inc. (RCKT) is followed by 5 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does Rocket Pharmaceuticals, Inc.(RCKT) do ?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Rocket Pharmaceuticals, Inc. (RCKT) Insider Trades

Multiple company employees have indulged in significant insider trading. Rocket Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, 10%, Rtw Investments, LP : P – Purchase(+$5,006,250) of RCKT in the trading session of 2019-12-10.

Dir, 10% Rtw Investments, LP : P – Purchase(+$9,625,088) of RCKT in the trading session of 2019-04-16.

See Remarks Shah Gaurav : S – Sale(-$1,286,272) of Rocket Pharmaceuticals, Inc. in the trading session of 2019-03-01.

Looking for stocks just like RCKT?

Based on Wall Street analyst research, several stocks are similar to RCKT
They are:
– AERI [Info can be found here: ]
– OCUL [Info can be found here: ]
– EYPT [Info can be found here: ]